Biocompatible Polymer Nano-Constructs: A Potent Platform for Cancer Theranostics.

Technol Cancer Res Treat

School of Engineering, 560377MIT-ADT University, Pune, Maharashtra, India.

Published: March 2023

AI Article Synopsis

  • Nano-constructs made from biocompatible polymers are gaining interest for their potential use in cancer treatment and detection at the same time.
  • The review discusses different types of polymer nano-architectures that have been created to function as theranostic agents, effectively combining therapy and diagnosis in one system.
  • Future research opportunities for improving polymer-based cancer theranostics are also explored in the review.

Article Abstract

Nano-constructs of biocompatible polymers have drawn wide attention owing to their potential as theranostics for simultaneous therapy and detection of cancer. The present mini review summarizes various nano-architectures of polymers that have been developed as theranostic agents for the simultaneous treatment and diagnosis of cancer in a single platform. Additionally, research prospects of polymeric cancer theranostics for the future have been highlighted.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9983094PMC
http://dx.doi.org/10.1177/15330338231160391DOI Listing

Publication Analysis

Top Keywords

cancer theranostics
8
biocompatible polymer
4
polymer nano-constructs
4
nano-constructs potent
4
potent platform
4
cancer
4
platform cancer
4
theranostics nano-constructs
4
nano-constructs biocompatible
4
biocompatible polymers
4

Similar Publications

RNA-binding motif protein RBM39 enhances the proliferation of gastric cancer cells by facilitating an oncogenic splicing switch in MRPL33.

Acta Pharmacol Sin

January 2025

Jiangsu Key Laboratory of Neuropsychiatric Diseases and College of Pharmaceutical Sciences, The Fourth Affiliated Hospital of Soochow University, Jiangsu Province Engineering Research Center of Precision Diagnostics and Therapeutics Development, Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Suzhou Key Laboratory of Drug Research for Prevention and Treatment of Hyperlipidemic Diseases, Soochow University, Suzhou, 215123, China.

Gastric cancer is a malignant gastrointestinal disease characterized by high morbidity and mortality rates worldwide. The occurrence and progression of gastric cancer are influenced by various factors, including the abnormal alternative splicing of key genes. Recently, RBM39 has emerged as a tumor biomarker that regulates alternative splicing in several types of cancer.

View Article and Find Full Text PDF

Purpose Of Review: This review aims to evaluate the impact of artificial intelligence (AI) on cancer health equity, specifically investigating whether AI is addressing or widening disparities in cancer outcomes.

Recent Findings: Recent studies demonstrate significant advancements in AI, such as deep learning for cancer diagnosis and predictive analytics for personalized treatment, showing potential for improved precision in care. However, concerns persist about the performance of AI tools across diverse populations due to biased training data.

View Article and Find Full Text PDF

The forward design of biosensors that implement Boolean logic to improve detection precision primarily relies on programming genetic components to control transcriptional responses. However, cell- and gene-free nanomaterials programmed with logical functions may present lower barriers for clinical translation. Here we report the design of activity-based nanosensors that implement AND-gate logic without genetic parts via bi-labile cyclic peptides.

View Article and Find Full Text PDF

Circulating tumor cells (CTCs) drive metastasis, the leading cause of death in individuals with breast cancer. Due to their low abundance in the circulation, robust CTC expansion protocols are urgently needed to effectively study disease progression and therapy responses. Here we present the establishment of long-term CTC-derived organoids from female individuals with metastatic breast cancer.

View Article and Find Full Text PDF

Point mutations in the ligand binding domain of retinoic acid receptor alpha (RARα) are linked to breast fibroepithelial tumor development, but their role in solid tumorigenesis is unclear. In this study, we assessed the functional effects of known RARα mutations on retinoic acid signaling using biochemical and cellular assays. All tested mutants exhibited reduced transcriptional activity compared to wild-type RARα and showed a dominant negative effect, a feature associated with developmental defects and tumor formation.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!